ACUTE MYELOID LEUKEMIA IN ELDERLY PATIENTS. ANALYSIS OF 102 CASES
(Abstract release date: 05/19/16)
EHA Library. Ionita H. 06/09/16; 134577; PB1677
Prof. Hortensia Ionita
Contributions
Contributions
Abstract
Abstract: PB1677
Type: Publication Only
Background
Acute myeloid leukemia (AML) is more frequent in elderly patients and the prognosis is very poor. There is no established standard treatment, since the survival of patients treated with intensive chemotherapy is 15% at 3 years. Most patients are not candidates for intensive treatment due to age, comorbidity or other biological characteristics. The management of old patients with AML remains controversial, specially in those cases affecting very old patients (aged ≥70).
Aims
It is presented the experience of our centre (single centre experience) with a group of patients from the period 1995-2014.
Methods
We conducted a retrospective analysis of 102 consecutive patients 65years of age or older, diagnosed for AML between January 1995 and December 2014, in Department of Hematology, County Hospital, Timisoara, Romania. Without selection (33.1%) had evolved from prior myelodysplastic syndrome. Patients were divided into 3 groups according to the treatment: no treatment (supportive treatment), low intensity treatment (low doses Ara-C: 10 mg/m2/12h s. c. days 1-21) and high intensity treatment (Idarubicin 10 mg/m2 days 1 and 3; Ara-C 100 mg/m2/12h days 1-3; Etoposide 100 mg/m2 days 1-3).
Results
Total number of subjects was 57 men and 45 women. Median patient age was 73 years (range, 65-87 years); mean Karnofsky index was 70; 72 patients received treatment and 30 of them did not; M3 subtype was excluded, overall survival was 6,2 months, significant differences were observed in the mean overall survival between the treated and no-treated groups (12,5 vs 2,5 months respectively; p=0,015). The patients treated with supportive therapy had a median length of hospital stay of 16 days, while the patients treated with chemotherapy had a median length of hospital stay of 75 days. In the low intensity group (45 patients) an overall response of 30% was observed; in the high intensity one (27 patients), overall response was 50% no statistical differences were observed between both groups considering all subgroups of response (p=0,14).
Conclusion
Overall survival in the treated group is higher than in the non-treated one, differences reached statistical significance. Comparing both arms of treatment no statistical differences were observed in the quality of response, though a higher proportion of complete responses were observed in the high intensity group. An adequate selection of patients for chemotherapy treatment leads to a low mortality rate. Further research is needed to establish optimal management and improve outcomes of elderly patients with AML.
Session topic: E-poster
Type: Publication Only
Background
Acute myeloid leukemia (AML) is more frequent in elderly patients and the prognosis is very poor. There is no established standard treatment, since the survival of patients treated with intensive chemotherapy is 15% at 3 years. Most patients are not candidates for intensive treatment due to age, comorbidity or other biological characteristics. The management of old patients with AML remains controversial, specially in those cases affecting very old patients (aged ≥70).
Aims
It is presented the experience of our centre (single centre experience) with a group of patients from the period 1995-2014.
Methods
We conducted a retrospective analysis of 102 consecutive patients 65years of age or older, diagnosed for AML between January 1995 and December 2014, in Department of Hematology, County Hospital, Timisoara, Romania. Without selection (33.1%) had evolved from prior myelodysplastic syndrome. Patients were divided into 3 groups according to the treatment: no treatment (supportive treatment), low intensity treatment (low doses Ara-C: 10 mg/m2/12h s. c. days 1-21) and high intensity treatment (Idarubicin 10 mg/m2 days 1 and 3; Ara-C 100 mg/m2/12h days 1-3; Etoposide 100 mg/m2 days 1-3).
Results
Total number of subjects was 57 men and 45 women. Median patient age was 73 years (range, 65-87 years); mean Karnofsky index was 70; 72 patients received treatment and 30 of them did not; M3 subtype was excluded, overall survival was 6,2 months, significant differences were observed in the mean overall survival between the treated and no-treated groups (12,5 vs 2,5 months respectively; p=0,015). The patients treated with supportive therapy had a median length of hospital stay of 16 days, while the patients treated with chemotherapy had a median length of hospital stay of 75 days. In the low intensity group (45 patients) an overall response of 30% was observed; in the high intensity one (27 patients), overall response was 50% no statistical differences were observed between both groups considering all subgroups of response (p=0,14).
Conclusion
Overall survival in the treated group is higher than in the non-treated one, differences reached statistical significance. Comparing both arms of treatment no statistical differences were observed in the quality of response, though a higher proportion of complete responses were observed in the high intensity group. An adequate selection of patients for chemotherapy treatment leads to a low mortality rate. Further research is needed to establish optimal management and improve outcomes of elderly patients with AML.
Session topic: E-poster
Abstract: PB1677
Type: Publication Only
Background
Acute myeloid leukemia (AML) is more frequent in elderly patients and the prognosis is very poor. There is no established standard treatment, since the survival of patients treated with intensive chemotherapy is 15% at 3 years. Most patients are not candidates for intensive treatment due to age, comorbidity or other biological characteristics. The management of old patients with AML remains controversial, specially in those cases affecting very old patients (aged ≥70).
Aims
It is presented the experience of our centre (single centre experience) with a group of patients from the period 1995-2014.
Methods
We conducted a retrospective analysis of 102 consecutive patients 65years of age or older, diagnosed for AML between January 1995 and December 2014, in Department of Hematology, County Hospital, Timisoara, Romania. Without selection (33.1%) had evolved from prior myelodysplastic syndrome. Patients were divided into 3 groups according to the treatment: no treatment (supportive treatment), low intensity treatment (low doses Ara-C: 10 mg/m2/12h s. c. days 1-21) and high intensity treatment (Idarubicin 10 mg/m2 days 1 and 3; Ara-C 100 mg/m2/12h days 1-3; Etoposide 100 mg/m2 days 1-3).
Results
Total number of subjects was 57 men and 45 women. Median patient age was 73 years (range, 65-87 years); mean Karnofsky index was 70; 72 patients received treatment and 30 of them did not; M3 subtype was excluded, overall survival was 6,2 months, significant differences were observed in the mean overall survival between the treated and no-treated groups (12,5 vs 2,5 months respectively; p=0,015). The patients treated with supportive therapy had a median length of hospital stay of 16 days, while the patients treated with chemotherapy had a median length of hospital stay of 75 days. In the low intensity group (45 patients) an overall response of 30% was observed; in the high intensity one (27 patients), overall response was 50% no statistical differences were observed between both groups considering all subgroups of response (p=0,14).
Conclusion
Overall survival in the treated group is higher than in the non-treated one, differences reached statistical significance. Comparing both arms of treatment no statistical differences were observed in the quality of response, though a higher proportion of complete responses were observed in the high intensity group. An adequate selection of patients for chemotherapy treatment leads to a low mortality rate. Further research is needed to establish optimal management and improve outcomes of elderly patients with AML.
Session topic: E-poster
Type: Publication Only
Background
Acute myeloid leukemia (AML) is more frequent in elderly patients and the prognosis is very poor. There is no established standard treatment, since the survival of patients treated with intensive chemotherapy is 15% at 3 years. Most patients are not candidates for intensive treatment due to age, comorbidity or other biological characteristics. The management of old patients with AML remains controversial, specially in those cases affecting very old patients (aged ≥70).
Aims
It is presented the experience of our centre (single centre experience) with a group of patients from the period 1995-2014.
Methods
We conducted a retrospective analysis of 102 consecutive patients 65years of age or older, diagnosed for AML between January 1995 and December 2014, in Department of Hematology, County Hospital, Timisoara, Romania. Without selection (33.1%) had evolved from prior myelodysplastic syndrome. Patients were divided into 3 groups according to the treatment: no treatment (supportive treatment), low intensity treatment (low doses Ara-C: 10 mg/m2/12h s. c. days 1-21) and high intensity treatment (Idarubicin 10 mg/m2 days 1 and 3; Ara-C 100 mg/m2/12h days 1-3; Etoposide 100 mg/m2 days 1-3).
Results
Total number of subjects was 57 men and 45 women. Median patient age was 73 years (range, 65-87 years); mean Karnofsky index was 70; 72 patients received treatment and 30 of them did not; M3 subtype was excluded, overall survival was 6,2 months, significant differences were observed in the mean overall survival between the treated and no-treated groups (12,5 vs 2,5 months respectively; p=0,015). The patients treated with supportive therapy had a median length of hospital stay of 16 days, while the patients treated with chemotherapy had a median length of hospital stay of 75 days. In the low intensity group (45 patients) an overall response of 30% was observed; in the high intensity one (27 patients), overall response was 50% no statistical differences were observed between both groups considering all subgroups of response (p=0,14).
Conclusion
Overall survival in the treated group is higher than in the non-treated one, differences reached statistical significance. Comparing both arms of treatment no statistical differences were observed in the quality of response, though a higher proportion of complete responses were observed in the high intensity group. An adequate selection of patients for chemotherapy treatment leads to a low mortality rate. Further research is needed to establish optimal management and improve outcomes of elderly patients with AML.
Session topic: E-poster
{{ help_message }}
{{filter}}